Skip to main content
SpringerLink
Log in

Adverse Cutaneous Reactions to Antipsychotics

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Antipsychotic agents are known to cause adverse cutaneous reactions in approximately 5% of the individuals for whom they are prescribed. The majority of adverse cutaneous events are benign and easily treated, and do not place the patient at a serious health risk. However, these adverse events may impact on compliance so discussing strategies with the patient to avoid potential adverse cutaneous effects will improve compliance. The most frequently reported cutaneous adverse effects of antipsychotic medications include: exanthematous eruptions, skin pigmentation changes, photosensitivity, urticaria and pruritus. Only a small percentage of adverse cutaneous reactions are life threatening. The most important step in minimizing morbidity is prompt recognition of severe drug reactions with withdrawal of the causative medication. If a skin eruption occurs in an outpatient setting, it is generally advisable to discontinue the drug and to consider switching to another class of agent. If the reaction is mild, and the therapeutic benefits far exceed the risks of the symptomatic treatment, then the antipsychotic agent may be continued.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Srebrnik A., Hes J.P., Brenner S. Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol 1991; 158: 3–12

    Google Scholar 

  2. Stahl S.M. Essential psychopharmacology: neuroscientific basis and practical application. 2nd ed. Cambridge: Cambridge University Press, 2000

    Google Scholar 

  3. Medical Economics. Physician’s desk reference. 55th ed. Montvale (NJ): Medical Economics, 2001

  4. Medical Economics. Physician’s desk reference. 48th ed. Montvale (NJ): Medical Economics, 1994

  5. Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996; 14 (3): 503–8

    Article  PubMed  CAS  Google Scholar 

  6. Pavlidakey G.P., Hashimoto K., Heller G.L., et al. Chlorpromazine-induced lupus-like disease: case report and review of the literature. J Am Acad Dermatol 1985; 13 (1): 109–15

    Article  PubMed  CAS  Google Scholar 

  7. MacMorran W.S., Krahn L.E. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997; 38 (5): 413–22

    Article  PubMed  CAS  Google Scholar 

  8. Gold M.S., Sweeney D.R. Perphenazine-induced systemic lupus erythematosus-like syndrome. J Nerv Ment Dis 1978; 166 (6): 442–5

    Article  PubMed  CAS  Google Scholar 

  9. McNevin S., MacKay M. Chlorprothixene-induced systemic lupus erythematosus. J Clin Psychopharmacol 1982; 2 (6): 411–2

    Article  PubMed  CAS  Google Scholar 

  10. Dubois E.L., Tallman E., Wonka R.A.. Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature. JAMA 1972; 221 (6): 595–6

    Article  PubMed  CAS  Google Scholar 

  11. Warnock J.K., Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988; 145: 425–30

    PubMed  CAS  Google Scholar 

  12. Scuderi S., Gift T.E. Thiothixene induced edema. Psychiatr Med 1986; 4 (3): 249–52

    PubMed  CAS  Google Scholar 

  13. Hamann G.L., Egan T.M., Wells B.G., et al. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 1990; 51 (12): 502–4

    PubMed  CAS  Google Scholar 

  14. Welsh A.L., Ede M. The fixed drug eruption. Arch Dermatol 1961; 84: 1012

    Article  Google Scholar 

  15. Reilly G.D., Wood M.L. Prochlorperazine: an unusual cause of lip ulceration. Acta Derm Venereol 1984; 64 (3): 270–1

    PubMed  CAS  Google Scholar 

  16. Matsuo I., Ozawa A., Niizuma K., et al. Lichenoid dermatitis due to chlorpromazine phototoxicity. Dermatologica 1979; 159 (1): 46–9

    Article  PubMed  CAS  Google Scholar 

  17. Eberlein-Konig B., Bindl A., Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997; 194 (2): 131–5

    Article  PubMed  CAS  Google Scholar 

  18. Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf 1996; 14 (4): 252–9

    Article  PubMed  CAS  Google Scholar 

  19. Fitzpatrick T.B., Johnson R.A., Wolff K., et al. Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw-Hill, 2001

    Google Scholar 

  20. Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191 (4): 263–8

    Article  PubMed  CAS  Google Scholar 

  21. Robins A.H. Phenothiazine melanosis in schizophrenic patients. Psychopharmacologia 1972; 27 (4): 327–42

    Article  PubMed  CAS  Google Scholar 

  22. Forrest F.M., Snow H.L., Erickson G., et al. Incidence of late ‘melanosis’ side effects in chronic mental patients after long term phenothiazine therapy. Proc West Pharmacol Soc 1966; 9: 18–20

    PubMed  CAS  Google Scholar 

  23. Gibbard B.A., Lehmann H.E. Therapy of phenothiazine-produced skin pigmentation: a preliminary report. Am J Psychiatry 1966; 123 (3): 351–2

    PubMed  CAS  Google Scholar 

  24. Berger H. Pigmentation after thioridazine [letter]. Arch Dermatol 1969; 100 (4): 487

    Article  PubMed  CAS  Google Scholar 

  25. Buckley C., Thomas V., Lewin J., et al. Stelazine-induced pigmentation. Clin Exp Dermatol 1994; 19 (2): 149–51

    Article  PubMed  CAS  Google Scholar 

  26. Lal S., Bloom D., Silver B., et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1993; 18 (4): 173–7

    PubMed  CAS  Google Scholar 

  27. Bloom D., Krishnan B., Thavundayil J.X., et al. Resolution of chlorpromazineinduced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. Acta Psychiatr Scand 1993; 87 (3): 223–4

    Article  PubMed  CAS  Google Scholar 

  28. Thompson T.R., Lal S., Yassa R., et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78 (6): 763–5

    Article  PubMed  CAS  Google Scholar 

  29. Ewing D.G., Einarson T.R. Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation. Am J Psychiatry 1981; 138 (12): 1631–2

    PubMed  CAS  Google Scholar 

  30. Lal S., Lal S. Chlorpromazine-induced cutaneous pigmentation: effect of replacement with clozapine [letter]. J Psychiatry Neurosci 2000; 25 (3): 281

    PubMed  CAS  Google Scholar 

  31. Lautenschlager S., Itin P.H. Reticulate, patchy and mottled pigmentation of the neck: acquired forms. Dermatology 1998; 197 (3): 291–6

    Article  PubMed  CAS  Google Scholar 

  32. Benning T.L., McCormack K.M., Ingram P., et al. Microprobe analysis of chlorpromazine pigmentation. Arch Dermatol 1988; 124 (10): 1541–4

    Article  PubMed  CAS  Google Scholar 

  33. Rohrborn W., Brauninger W. Thioridazine photoallergy [letter]. Contact Dermatitis 1987; 17 (4): 241

    Article  PubMed  CAS  Google Scholar 

  34. Suhonen R. Thioridazine photosensitivity [letter]. Contact Dermatitis 1976; 2 (3): 179

    Article  PubMed  CAS  Google Scholar 

  35. Satanove A., McIntosh J.S. Phototoxic reactions induced by high doses of chlorpromazine and thioridazine. JAMA 1967; 200 (3): 209–12

    Article  PubMed  CAS  Google Scholar 

  36. Torinuki W. Contact dermatitis to biperiden and photocontact dermatitis to phenothiazines in a pharmacist. Tohoku J Exp Med 1995; 176 (4): 249–52

    Article  PubMed  CAS  Google Scholar 

  37. Harth Y., Rapport M. Phototoxicity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996; 14: 252–9

    Article  PubMed  CAS  Google Scholar 

  38. Epstein J.H., Wintroub B.U. Photosensitivity due to drugs. Drugs 1985; 30 (1): 42–57

    Article  PubMed  CAS  Google Scholar 

  39. Ban T.A., Guy W., Wilson W.H. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30 (6): 406–8

    PubMed  CAS  Google Scholar 

  40. Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191: 263–8

    Article  PubMed  CAS  Google Scholar 

  41. Zelickson A.S. Skin pigmentation and chlorpromazine. JAMA 1965; 194 (6): 670–2

    Article  PubMed  CAS  Google Scholar 

  42. Greiner A.C., Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J 1964; 90: 663–4

    PubMed  CAS  Google Scholar 

  43. Chignell C.F., Motten A.G., Buettner G.R. Photoinduced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Environ Health Perspect 1985; 64: 103–10

    Article  PubMed  CAS  Google Scholar 

  44. King D.L. Neuroleptics and the treatment of schizophrenia. In: King D.L., editor, for the Royal College of Psychiatrists. Seminars in clinical psychopharmacology. London: Gaskell, 1995

    Google Scholar 

  45. Ban T.A., Guy W., Wilson WH. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30: 406–8

    PubMed  CAS  Google Scholar 

  46. Bond W.S., Yee G.C. Occular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm 1980; 37: 74–8

    PubMed  CAS  Google Scholar 

  47. Wolf M.E., Richer S., Berk M.A., et al. Cutaneous and ocular changes associated with the use of chlorpromazine. Int J Clin Pharmacol Ther Toxicol 1993; 31: 365–7

    PubMed  CAS  Google Scholar 

  48. Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60 (10): 714–25

    Article  PubMed  CAS  Google Scholar 

  49. Thompson T.R., Lai S., Yassa R., et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78: 763–5

    Article  PubMed  CAS  Google Scholar 

  50. Mercke Y., Sheng H., Khan T., et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12 (1): 35–42

    PubMed  CAS  Google Scholar 

  51. Kubota T., Ishikura T., Jibiki I. Alopecia areata associated with haloperidol. Jpn J Psychiatry Neurol 1994; 48: 579–81

    PubMed  CAS  Google Scholar 

  52. Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991; 32 (2): 149–52

    Article  PubMed  CAS  Google Scholar 

  53. Blankenship M.L. Drugs and alopecia. Australas J Dermatol 1983; 24: 100–4

    Article  PubMed  CAS  Google Scholar 

  54. Simpson G.H., Pi E.H., Sramek J.J. Neuroleptics and anti-psychotics. In: Dukes M.N.G., editor. Meyer’s side effects of drugs. Amsterdam: Elsevier, 1982: 95–108

    Google Scholar 

  55. Raz A., Bergman R., Eilam O., et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321 (2): 156–8

    Article  PubMed  CAS  Google Scholar 

  56. Flint A. The skin in Parkinson’s disease. Prim Care 1977; 4: 475–80

    PubMed  CAS  Google Scholar 

  57. Binder R.I., Jonelis F.J. Seborrheic dermatitis: a newly reported side effect of neuroleptics. J Clin Psychiatry 1984; 45: 125–6

    PubMed  CAS  Google Scholar 

  58. Binder R.I., Jonelis F.J. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 1983; 119: 473–5

    Article  PubMed  CAS  Google Scholar 

  59. Daoud M.S., Schanbacher C.F., Dicken C.H. Recognizing cutaneous drug eruptions: reaction patterns provide clues to causes. Postgrad Med 1998; 104: 101–15

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. University of Oklahoma Health Sciences Center, Room 2D25, 4502 East 41st Street, Tulsa, Oklahoma, 74135, USA

    Julia K. Warnock

  2. The University of Tulsa, Tulsa, Oklahoma, USA

    David W. Morris

Authors
  1. Julia K. Warnock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David W. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia K. Warnock.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warnock, J.K., Morris, D.W. Adverse Cutaneous Reactions to Antipsychotics. Am J Clin Dermatol 3, 629–636 (2002). https://doi.org/10.2165/00128071-200203090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200203090-00005

Keywords

Search

Navigation